7-[3,3-difluoro-5-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2-oxopyrrolidin-1-yl]heptanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-[3,3-difluoro-5-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2-oxopyrrolidin-1-yl]heptanoic acid
• 化学式: C₂₀H₂₉F₂NO₄
• 分子量: 385.4
• InChiKey: KWEXZQZQGLFDSE-PJCRGOGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
  申请人：Cayman Chemical Company, Inc.

  公开号：US10556862B2

  公开（公告）日：2020-02-11

  Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

  此处公开的是式 (I) 化合物 以及用式（I）化合物进行治疗的方法，其中 L1、L2、L4、R1、R4、R5、R6 和 s 如说明书中所定义。式（I）化合物是 EP4 激动剂，可用于治疗青光眼、神经性疼痛及相关疾病。
• DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS
  申请人：Cayman Chemical Company, Incorporated

  公开号：EP2875022B1

  公开（公告）日：2016-10-12
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS
  申请人：Cayman Chemical Company, Inc.

  公开号：US20170260173A1

  公开（公告）日：2017-09-14

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L 1 , L 2 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification.